Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.37 |
| ▸ | DPP4 | P27487 | 11/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 10/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581895 | 0.85 | NOTUM (0.33) | NOTUMDPP4DPP9DPP8DPP7 | |
| SCHEMBL3086468 | 0.85 | NOTUM (0.42) | NOTUMDPP4DPP9DPP8DPP7 | |
| SCHEMBL582014 | 0.83 | NOTUM (0.43) | NOTUMDPP4 | |
| SCHEMBL587099 | 0.81 | ALDH1A1 (0.34) | DPP4DPP9DPP8DPP7KDM4E | |
| SCHEMBL582163 | 0.81 | NOTUM (0.46) | NOTUMTSHRCYP2C19 | |
| SCHEMBL582066 | 0.81 | SLC6A9 (0.40) | NOTUMDPP4DPP9DPP8DPP7 | |
| SCHEMBL3081192 | 0.80 | NOTUM (0.37) | NOTUMDPP4DPP9DPP8DPP7 | |
| SCHEMBL586675 | 0.78 | FFAR4 (0.50) | NOTUMDPP4DPP8DPP7 | |
| SCHEMBL581861 | 0.78 | NOTUM (0.38) | NOTUM | |
| SCHEMBL586549 | 0.78 | FFAR2 (0.41) | NOTUMCYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | NOTUM 2559/4885DPP4 754/4885DPP9 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.